Distinct Sets of Genetic Alterations in Melanoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. METHODS: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. RESULTS: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. CONCLUSIONS: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these mutations are not UV-signature mutations20, they are more common in sun-exposed skin20–23.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Self-citationPinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., et al. (1998) · Nature Genetics · doi:10.1038/2524 · Cited by 2,240
Self-citationThe histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression
Cleveland, W. S. (1981) · The American Statistician · doi:10.2307/2683591 · Cited by 1,150
Cited by
Items 701–800 of 1,006
Babapoor, S., Fleming, E. S., Wu, R., & Dadras, S. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107502 · Cited by 55
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
Johansson, C. C., Egyházi, S., Masucci, G. V., Harlin, H., Mougiakakos, D., Poschke, I. C., Nilsson, B. R., Garberg, L., Tuominen, R., Lindén, D., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0631-1 · Cited by 55
Longo, C., Gambara, G., Espina, V. A., Luchini, A., Bishop, B., Patanarut, A., Petricoin, E. F., Beretti, F., Ferrari, B., Garaci, E., et al. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2010.01187.x · Cited by 55
Kinase gene fusions in defined subsets of melanoma
Turner, J. A., Couts, K. L., Sheren, J. E., Saichaemchan, S., Ariyawutyakorn, W., Avolio, I., Cabral, E., Glogowska, M., Amato, C. M., Robinson, S. E., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12560 · Cited by 55
Acral lentiginous melanoma versus other melanoma: A single‐center analysis in Japan
Wada, M., Ito, T., Tsuji, G., Nakahara, T., Hagihara, A., Furue, M., & Uchi, H. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13834 · Cited by 55
Reimann, J. D. R., Salim, S., Velázquez, E. F., Wang, L., Williams, K. M., Flejter, W. L., Brooke, L. M., Sunder, S., & BUSAM, K. J. (2018) · Modern Pathology · doi:10.1038/s41379-018-0087-6 · Cited by 55
Self-citationQuek, C. Y. J., Rawson, R. V., Ferguson, P. M., Shang, P., da Silva, I. P., Saw, R. P. M., Shannon, K. F., Thompson, J. F., Hayward, N. K., Long, G. V., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26584 · Cited by 55
New techniques in dermatopathology that help to diagnose and prognosticate melanoma
Carlson, J. A., Ross, J. S., & Slominski, A. T. (2008) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.007 · Cited by 55
Baxter, A. J., Hughes, M. C. B., Kvaskoff, M., Siskind, V., Shekar, S. N., Aitken, J. F., Green, A. C., Duffy, D. L., Hayward, N. K., Martin, N. G., et al. (2008) · Twin Research and Human Genetics · doi:10.1375/twin.11.2.183 · Cited by 55
Casula, M., Muggiano, A., Cossu, A., Budroni, M., Caracò, C., Ascierto, P. A., Pagani, E., Stanganelli, I., Canzanella, S., Sini, M. C., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-352 · Cited by 55
Schultz, J., Ibrahim, S. M., Vera, J., & Kunz, M. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-53 · Cited by 55
A novel tumor suppressor function of Kindlin-3 in solid cancer
Djaafri, I., Khayati, F., Ménashi, S., Tost, J., Podgorniak, M.-P., Sadoux, A., Daunay, A., Teixeira, L., Soulier, J., Idbaïh, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2125 · Cited by 54
Variations of BRAF mutant allele percentage in melanomas
Hélias‐Rodzewicz, Z., Funck‐Brentano, E., Baudoux, L., Jung, C. K., Zimmermann, U. S., Marin, C., Clérici, T., Gall, C. L., Peschaud, F., Taly, V., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1515-3 · Cited by 54
Immunotherapy for advanced melanoma: Fulfilling the promise
Gogas, H. J., Polyzos, A., & Kirkwood, J. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.04.006 · Cited by 54
3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines
Qin, J.-Z., Xin, H., & Nickoloff, B. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.126 · Cited by 54
The structural basis for cancer treatment decisions
Nussinov, R., Jang, H., & Tsai, C.-J. (2014) · Oncotarget · doi:10.18632/oncotarget.2439 · Cited by 49
Genetic alterations in RAS ‐regulated pathway in acral lentiginous melanoma
Puig‐Butillé, J. A., Bádenas, C., Ogbah, Z., Carrera, C., Aguilera, P., Malvehy, J., & Puig, S. (2012) · Experimental Dermatology · doi:10.1111/exd.12080 · Cited by 54
Vujic, I., Sanlorenzo, M., Esteve‐Puig, R., Vujic, M., Kwong, A., Tsumura, A., Murphy, R. M., Moy, A., Posch, C., Itzinger-Monshi, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6907 · Cited by 54
Liu, M., Yang, X., Liu, J., Zhao, B., Cai, W., Li, Y., & Hu, D. (2017) · Oncotarget · doi:10.18632/oncotarget.15632 · Cited by 54
BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma
Bai, X. L., Mao, L., H., Z., SHENG, X. N., Cui, C.-L., Kong, Y., Dai, J., WANG, X., Li, S., Tang, B. X., et al. (2017) · Neoplasma · doi:10.4149/neo_2017_419 · Cited by 54
ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Couts, K. L., Bemis, J. G. T., Turner, J. A., Bagby, S. M., Murphy, D. A., Christiansen, J., Hintzsche, J. D., Le, A. T., Pitts, T. M., Wells, K. R., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0472 · Cited by 54
Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Wahid, M., Jawed, A., Mandal, R. K., Dar, S. A., Akhter, N., Somvanshi, P., Khan, F., Lohani, M., Areeshi, M. Y., & Haque, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.005 · Cited by 54
MEK inhibitors for the treatment of NRAS mutant melanoma
Sarkisian, S., & Davar, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s131721 · Cited by 55
Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma
Cohen, J. V., & Sullivan, R. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0836 · Cited by 54
Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma
Sini, M. C., Manca, A., Cossu, A., Budroni, M., Botti, G., Ascierto, P. A., Cremona, F., Muggiano, A., D’Atri, S., Casula, M., et al. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08310.x · Cited by 54
Genomic characterisation of acral melanoma cell lines
Furney, S. J., Turajlic, S., Fenwick, K., Lambros, M. B. K., Mackay, A. G., Ricken, G., Mitsopoulos, C., Kozarewa, I., Hakas, J., Zvelebil, M., et al. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.01016.x · Cited by 54
Gumaste, P. V., Fleming, N. H., da Silva, I. P., Shapiro, R. L., Berman, R. S., Zhong, J., Osman, I., & Stein, J. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0172 · Cited by 55
Combination of targeted therapy and immunotherapy in melanoma
Blank, C. U., Hooijkaas, A. I., Haanen, J. B. A. G., & Schumacher, T. N. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1079-2 · Cited by 54
Targeted therapy in rare cancers—adopting the orphans
Munoz, J. L., & Kurzrock, R. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.160 · Cited by 53
Co-development of a companion diagnostic for targeted cancer therapy
Cheng, S., Koch, W. H., & Wu, L. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.02.002 · Cited by 53
Oba, J., Nakahara, T., Abe, T., Hagihara, A., Moroi, Y., & Furue, M. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.02.011 · Cited by 53
Oncolytic Virus Immunotherapy for Melanoma
Dharmadhikari, N. D., Mehnert, J. M., & Kaufman, H. L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0326-0 · Cited by 53
Current management of melanoma
Dunki-Jacobs, E. M., Callender, G. G., & McMasters, K. M. (2013) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2013.04.001 · Cited by 53
Towards new therapeutic approaches for malignant melanoma
Pacheco, I., Buzea, C., & Tron, V. A. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239941100202x · Cited by 54
Yamada, K., Ono, M., Perkins, N. D., Rocha, S., & Lamond, A. I. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.12.023 · Cited by 53
Cui, Y., Borysova, M. K., Johnson, J., & Guadagno, T. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1491 · Cited by 53
Leachman, S. A., Cassidy, P. B., Chen, S. C., Curiel, C. N., Geller, A. C., Gareau, D. S., Pellacani, G., Grichnik, J. M., Malvehy, J., North, J. P., et al. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_3 · Cited by 53
Madankumar, R., Gumaste, P. V., Martires, K. J., Schaffer, P. R., Choudhary, S., Falto-Aizpurua, L. A., Arora, H., Kallis, P. J., Patel, S. B., Damanpour, S., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.11.035 · Cited by 53
Lentigo Maligna: Clinical Presentation and Appropriate Management
Iznardo, H., García‐Melendo, C., & Yélamos, O. (2020) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s224738 · Cited by 53
Filimon, A., Preda, I. A., Boloca, A. F., & Negroiu, G. (2021) · Cells · doi:10.3390/cells11010120 · Cited by 53
Pathways of oncogene-induced senescence in human melanocytic cells
Bansal, R., & Nikiforov, M. A. (2010) · Cell Cycle · doi:10.4161/cc.9.14.12251 · Cited by 54
Matsukuma, S., Yoshihara, M., Kasai, F., Kato, A., Yoshida, A., Akaike, M., Kobayashi, O., Nakayama, H., Sakuma, Y., Yoshida, T., et al. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.060030 · Cited by 53
Cust, A. E., Schmid, H., Maskiell, J., Jetann, J., Ferguson, M., Holland, E. A., Agha‐Hamilton, C., Jenkins, M. A., Kelly, J. W., Kefford, R. F., et al. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp307 · Cited by 53
Targeting KRAS G12C with Covalent Inhibitors
Ostrem, J. M. L., & Shokat, K. M. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041621-012549 · Cited by 52
New Approaches to Targeted Therapy in Melanoma
Fernandez, M. F., Choi, J. S., & Sosman, J. A. (2023) · Cancers · doi:10.3390/cancers15123224 · Cited by 52
Walker, G. J., Soyer, H. P., Terzian, T., & Box, N. F. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00923.x · Cited by 52
PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells
Mannava, S., Omilian, A. R., Wawrzyniak, J. A., Fink, E. E., Zhuang, D., Miecznikowski, J. C., Marshall, J. R., Soengas, M. S., Sears, R. C., Morrison, C. D., et al. (2012) · Oncogene · doi:10.1038/onc.2011.339 · Cited by 42
Niu, H., Zhou, Q., Wang, F., Shao, Q., Guan, Y., Wen, X., Chen, L., Feng, Q., Li, W., Zeng, Y., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12129 · Cited by 52
Targeted Molecular Therapy in Melanoma
Puzanov, I. J., & Flaherty, K. T. (2010) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2010.06.005 · Cited by 52
RetractedThe role of MEK inhibitors in the treatment of metastatic melanoma
Grimaldi, A. M., Simeone, E., & Ascierto, P. A. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000050 · Cited by 52
Schultz, J., Lorenz, P., Ibrahim, S. M., Kundt, G., Gross, G., & Kunz, M. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20452 · Cited by 52
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 52
Voltaggio, L., Cimino‐Mathews, A., Bishop, J. A., Argani, P., Cuda, J. D., Epstein, J. I., Hruban, R. H., Netto, G. J., Stoler, M. H., Taube, J. M., et al. (2016) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21350 · Cited by 52
Circulating Biomarkers in Malignant Melanoma
Alegre, E., Sammamed, M., Landazuri, S. F., Zubiri, L., & González, Á. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2014.12.002 · Cited by 55
Nagore, E., Hueso, L., Estrada, R. B., Alfaro‐Rubio, A., de la Serna, I., Guallar, J., González, I., Ribes, I., & Guillén, C. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03353.x · Cited by 54
Pracht, M., Mogha, A., Lespagnol, A., Fautrel, A., Mouchet, N., Gall, F. L., Paumier, V., Lefeuvre‐Plesse, C., Rioux-Leclercq, N. C., Mosser, J., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12910 · Cited by 52
Mantovani, G., Bondioni, S., Lania, A. G., Rodolfo, M., Peverelli, E., Polentarutti, N., Rodriguez, T. V., Ferrero, S., Bòsari, S., Beck‐Peccoz, P., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210831 · Cited by 52
RetractedDelston, R. B., Matatall, K. A., Sun, Y., Onken, M. D., & Harbour, J. W. (2010) · Oncogene · doi:10.1038/onc.2010.442 · Cited by 54
BRAF mutations in pediatric metanephric tumors
Chami, R., Yin, M., Marrano, P. M., Teerapakpinyo, C., Shuangshoti, S., & Thorner, P. S. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.03.019 · Cited by 51
Park, J. J., Hawryluk, E. B., Tahan, S. R., Flaherty, K. T., & Kim, C. C. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.7919 · Cited by 51
Kutzner, H., Metzler, G., Argényi, Z. B., Requena, L., Palmedo, G., Mentzel, T., Rütten, A., Hantschke, M., Paredes, B. E., Schärer, L., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.35 · Cited by 51
Self-citationChang, Y., Gao, H., Chiang, C., Wang, W., Huang, S., Ku, C.-F., Liu, G., & Hung, H. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.385 · Cited by 51
Sarı, Ş. Ö., Yılmaz, İ., Taşkın, O. Ç., Narlı, G., Şen, F., Çomoğlu, Ş., Firat, P., Bılgıç, B., Yılmazbayhan, D., Özlük, Y., et al. (2016) · Pathology · doi:10.1016/j.pathol.2016.09.065 · Cited by 51
Dantonio, P. M., Klein, M., Freire, M. R. V. B., Araujo, C. D. N., Chiacetti, A. C., & Correa, R. G. (2018) · Bioscience Reports · doi:10.1042/bsr20180511 · Cited by 52
Chemopreventive Effects of Licorice and Its Components
Bode, A. M., & Dong, Z. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-014-0015-5 · Cited by 51
NRAS and BRAF mutation frequency in primary oral mucosal melanoma
Buery, R. R., Siar, C. H., Katase, N., Gunduz, M., Lefeuvre, M., Fujii, M., Inoue, M., Setsu, K., & Nagatsuka, H. (2011) · Oncology Reports · doi:10.3892/or.2011.1385 · Cited by 51
Sekulić, A., Kim, S. Y., Hostetter, G. H., Savage, S., Einspahr, J. G., Prasad, A. R., Sagerman, P. J., Curiel‐Lewandrowski, C. N., Krouse, R. S., Bowden, G. T., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0058 · Cited by 51
Oropharyngeal Cancer, Human Papilloma Virus, and Clinical Trials
Rischin, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9045 · Cited by 51
Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes
Wang, M., Banik, I., Shain, A. H., Yeh, I., & Bastian, B. C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01068-0 · Cited by 50
Self-citationTrametinib in the treatment of melanoma
Thota, R., Johnson, D. B., & Sosman, J. A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1026323 · Cited by 52
Luke, J. J., & Ott, P. A. (2014) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s39568 · Cited by 50
High Throughput Mass Spectrometry-Based Mutation Profiling of Primary Uveal Melanoma
Daniels, A. B., Lee, J., MacConaill, L. E., Palescandolo, E., Hummelen, P. V., Adams, S. M., DeAngelis, M. M., Hahn, W. C., Gragoudas, E. S., Harbour, J. W., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10427 · Cited by 50
Targeted therapy for NSCLC with driver mutations
Minuti, G., D’Incecco, A., & Cappuzzo, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.827657 · Cited by 52
Cui, Y., & Guadagno, T. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210972 · Cited by 50
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Caputo, E., Miceli, R., Motti, M. L., Taté, R., Fratangelo, F., Botti, G., Mozzillo, N., Carriero, M. V., Cavalcanti, E., Palmieri, G., et al. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0216-z · Cited by 48
Ugurel, S., Utikal, J. S., & Becker, J. C. (2009) · Cancer Control · doi:10.1177/107327480901600303 · Cited by 50
Egan, K. M. (2009) · Annals of Epidemiology · doi:10.1016/j.annepidem.2009.01.005 · Cited by 49
Kiuru, M. H., Tartar, D. M., Qi, L., Chen, D., Yu, L., Konia, T. H., McPherson, J. D., Murphy, W. J., & Fung, M. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.052 · Cited by 50
Griewank, K., Koelsche, C., van de Nes, J. A. P., Schrimpf, D., Gessi, M., Möller, I., Sucker, A., Scolyer, R. A., Buckland, M. E., Murali, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0763 · Cited by 50
The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
Wei, X., Wu, D., Li, H., Zhang, R., Chen, Y., Yao, H., Chi, Z., Sheng, X., Cui, C., Bai, X. L., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08418-5 · Cited by 51
Genetic and Genomic Pathways of Melanoma Development, Invasion and Metastasis
Motwani, J., & Eccles, M. R. (2021) · Genes · doi:10.3390/genes12101543 · Cited by 50
Cutaneous melanoma: A model to study cancer metastasis
Leong, S. P. L., Gershenwald, J. E., Soong, S.-J., Schadendorf, D., Tarhini, A. A., Agarwala, S. S., Hauschild, A., Soon, C. W. M., DAUD, A. I., & Kashani‐Sabet, M. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21816 · Cited by 50
Wei, B., Michael, H. T., Halsey, C., Peer, C. J., Adhikari, A. S., Dwyer, J. E., Hoover, S. B., Meskini, R. E., Kozlov, S. V., Ohler, Z. W., et al. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12512 · Cited by 50
An update on the implications of cyclin D1 in melanomas
González‐Ruiz, L., González‐Moles, M. Á., González‐Ruiz, I., Ruiz‐Ávila, I., Ayén, Á., & Ramos‐García, P. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12874 · Cited by 49
Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection
Zhang, B., & Finn, R. S. (2016) · Liver Cancer · doi:10.1159/000367763 · Cited by 49
The genetic evolution of acral melanoma
Wang, M., Fukushima, S., Sheen, Y., Ramelyte, E., Cruz‐Pacheco, N., Shi, C., Liu, S., Banik, I., Aquino, J. D., Acosta, M. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50233-z · Cited by 50
Self-citationA Review of Melanoma Subtypes: Genetic and Treatment Considerations
Druskovich, C., Kelley, J. K., Aubrey, J. M., Palladino, L., & Wright, G. P. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27953 · Cited by 50
Steroid hormone influence on melanomagenesis
Mitkov, M. V., Joseph, R. W., & Copland, J. A. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.020 · Cited by 49
Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites
Sekine, S., Nakanishi, Y., Ogawa, R., Kouda, S., & Kanai, Y. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0762-6 · Cited by 49
Grunsven, A. C. H. V. E., Küsters‐Vandevelde, H. V. N., de Hullu, J. A., van Duijn, L. M., Rijntjes, J., Bovée, J. V. M. G., Groenen, P. J. T. A., & Blokx, W. A. M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.056 · Cited by 49
Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells
Kaushik, G., Ramalingam, S., Subramaniam, D., Rangarajan, P., Protti, P., Rammamoorthy, P., Anant, S., & Mammen, J. M. V. (2012) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2012.09.001 · Cited by 49
microRNA in situ hybridization for miR-211 detection as an ancillary test in melanoma diagnosis
Babapoor, S., Horwich, M. D., Wu, R., Levinson, S., Gandhi, M., Makkar, H. S., Kristjansson, A. K., Chang, M., & Dadras, S. S. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.44 · Cited by 49
Bianchi, A., Bagati, A., Fink, E. E., Moparthy, S., Wawrzyniak, J. A., Marvin, E. K., Battaglia, S., Jowdy, P., Kolesnikova, M., Foley, C. E., et al. (2016) · Oncogene · doi:10.1038/onc.2016.178 · Cited by 49
Energy metabolism in skin cancers: A therapeutic perspective
Hosseini, M., Kasraian, Z., & Rezvani, H. R. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.01.013 · Cited by 50
Targeting malignant melanoma with physical plasmas
Pasqual-Melo, G., Gandhirajan, R. K., Stoffels, I., & Bekeschus, S. (2018) · Clinical Plasma Medicine · doi:10.1016/j.cpme.2018.03.001 · Cited by 49
Preusser, M., Mattos‐Arruda, L. D., Thill, M., Criscitiello, C., Bartsch, R., Ruhstaller, T., de Azambuja, E., & Zielinski, C. C. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000368 · Cited by 49
Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis
Thomas, N. E., Edmiston, S. N., Tsai, Y., Parker, J. S., Googe, P. B., BUSAM, K. J., SCOTT, G. A., Zedek, D. C., Parrish, E., Hao, H., et al. (2018) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001259 · Cited by 49
Self-citationSubungual Melanoma of the Hand
Chakera, A. H., Quinn, M. J., Lo, S., Drummond, M., Haydu, L. E., Bond, J. S., Stretch, J. R., Saw, R. P. M., Lee, K. J., McCarthy, W. H., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-07094-w · Cited by 49
Insights into melanoma: targeting the mTOR pathway for therapeutics
Pópulo, H., Soares, P., & Lopes, J. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.691472 · Cited by 50
An Overview of the Changing Landscape of Treatment for Advanced Melanoma
Lee, C., Thomas, C. M., & Ng, K. E. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1895 · Cited by 49
Metadata
- Authors
- Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., Pinkel, D., & Bastian, B. C.
- Affiliations
- University of California, San Francisco (US)
- Kumamoto University Hospital (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Dermatopathologie Friedrichshafen (DE)
- Seoul National University (KR)
- Tohoku University (JP)
- University of Würzburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2135-2147
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989121777
- Cited by
- 2,747
- References
- 38
- Citations by year
- 2026: 54 · 2025: 69 · 2024: 87 · 2023: 91 · 2022: 85 · 2021: 125 · 2020: 165 · 2019: 133 · 2018: 130 · 2017: 164 · 2016: 157 · 2015: 170 · 2014: 197 · 2013: 218 · 2012: 202
- FWCI
- 33.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (R01CA094963, R33 CA95300, R33CA095300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- melanoma, UV exposure, acral melanoma, mucosal melanoma, BRAF mutation, NRAS mutation, copy number alterations, CDK4, CCND1, oncogenes, tumor genetic heterogeneity, skin cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Environmental Exposure, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Nucleic Acid Hybridization, Genes, ras, Risk Factors, Skin Neoplasms, Ultraviolet Rays, Signal Transduction, Genome, Human, Phosphatidylinositol 3-Kinases, Cyclin D1, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.